Turnstone Biologics Corp (TSBX)

$0.35 0.00 (-0.93%)
Market Cap 8.10M
Revenue (ttm) 0.00
Net Income (ttm) -70.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 82,800
Avg Vol 453,286
Day's Range N/A - N/A
Shares Out 23.14M
Stochastic %K 21%
Beta 1.36
Analysts Hold
Price Target $1.00

Company Profile

Turnstone Biologics Corp. operates as a biotechnology company. The company was founded in 2014 and is headquartered in San Diego, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 347 897 5988
Address:
9310 Athena Circle, Suite 300, San Diego, United States
DCZ
DCZ Jul. 16 at 5:27 PM
$TSBX is everyone tendering their shares? I held out on the first offer when this happened to BLUE and they made a better offer a few weeks later. I know this is a different situation but typically someone’s first offer is never their best offer.
1 · Reply
joe77w
joe77w Jun. 30 at 12:13 PM
$TSBX how much could be worth the CVR? 8/10 cents? Or less?
2 · Reply
Stmkr
Stmkr Jun. 28 at 5:41 AM
$TSBX $XOMA I dont get it. What does XOMA get from this acquisition??
1 · Reply
joe77w
joe77w Jun. 27 at 10:38 PM
$TSBX https://www.otcmarkets.com/filing/html?id=18580209&guid=nOi-kFPioonXB3h
0 · Reply
Chi_Booth
Chi_Booth Jun. 27 at 9:29 PM
$TSBX Looks like the net cash will be a separate distribution. As of last Q, they had $21M of cash and $7M of liabilities. They also appear to be selling certain assets to Moffit for $3M, which could be an additional upside. This deal could end up being a dollar or slightly under.
1 · Reply
ikkydiphoenix
ikkydiphoenix Jun. 27 at 8:50 PM
$TSBX Ms. Azmat will be eligible to receive, on the Azmat Separation Date, a cash severance payment in the amount of $354,327, COBRA benefits in the amount of $8,218.49, and outplacement services in the amount of up to $5,000. In addition, effective and contingent upon the closing of the Merger, Ms. Azmat will be entitled to receive an additional payment equal to $64,035. Ehi Good Job Guys, i could have reached a better deal with a 1000$ salary by the way :D
0 · Reply
ikkydiphoenix
ikkydiphoenix Jun. 27 at 8:49 PM
$TSBX Dr. Farah will be eligible to receive, on the Farah Separation Date, a cash severance payment in the amount of $686,757, COBRA benefits in the amount of $33,264.60, and outplacement services in the amount of up to $5,000. In addition, effective and contingent upon the closing of the Merger, Dr. Farah will be entitled to receive an additional payment equal to $148,874.68. LOL
0 · Reply
ikkydiphoenix
ikkydiphoenix Jun. 27 at 8:44 PM
$TSBX Each CVR holder will be entitled to the right to receive its portion of the amount equal to (i) up to an aggregate amount for all CVR holders of $1,110,000 to the extent received by the Company as a result of contingent payments relating to tax receivables and a lease security deposit, plus (ii) Net Cash Excess (as defined in the CVR Agreement), and minus (iii) Net Cash Shortfall (as defined in the CVR Agreement) (“CVR Proceeds”). In the event that any such CVR Proceeds are received after one year following the date of the closing of the Merger, holders of the CVRs will not receive any payment pursuant to the CVR Agreement.
1 · Reply
Chi_Booth
Chi_Booth Jun. 27 at 8:37 PM
$TSBX How do you accept an $8M BO offer when you have $20M in cash? If CVR is worth more than the cash value, why not spell it out for the shareholders? This is just messed up, and I am pissed at the level of incompetence. 😡
0 · Reply
Chi_Booth
Chi_Booth Jun. 27 at 8:28 PM
$TSBX This management team is seriously retarded!
0 · Reply
Latest News on TSBX
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights

May 8, 2025, 6:00 PM EDT - 3 months ago

Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 28, 2025, 9:03 PM EDT - 4 months ago

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 5, 2024, 9:01 AM EST - 9 months ago

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study

Aug 15, 2024, 11:57 AM EDT - 1 year ago

Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study

Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer

Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

May 13, 2024, 5:01 PM EDT - 1 year ago

Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference

May 8, 2024, 9:00 AM EDT - 1 year ago

Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference

Turnstone Biologics Appoints William Waddill to its Board of Directors

Apr 16, 2024, 9:00 AM EDT - 1 year ago

Turnstone Biologics Appoints William Waddill to its Board of Directors

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

Mar 21, 2024, 5:06 PM EDT - 1 year ago

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

Turnstone Biologics to Participate in Upcoming Investor Conferences

Feb 21, 2024, 6:00 AM EST - 1 year ago

Turnstone Biologics to Participate in Upcoming Investor Conferences

Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.

Feb 20, 2024, 5:00 PM EST - 1 year ago

Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.

Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference

Nov 27, 2023, 6:00 AM EST - 1 year ago

Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference

Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Nov 9, 2023, 9:49 PM EST - 1 year ago

Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 3, 2023, 6:00 AM EDT - 1 year ago

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber

Oct 30, 2023, 6:00 AM EDT - 1 year ago

Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber

Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 28, 2023, 6:00 AM EDT - 2 years ago

Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3

Sep 21, 2023, 5:11 AM EDT - 2 years ago

Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3

SCLX SGHT TNYA

Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update

Sep 1, 2023, 5:57 PM EDT - 2 years ago

Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update

FMR LLC Acquires Significant Stake in Turnstone Biologics Corp

Jul 27, 2023, 4:36 PM EDT - 2 years ago

FMR LLC Acquires Significant Stake in Turnstone Biologics Corp

Turnstone Biologics set to go public as upsized $80 million IPO pricing at low end of expected range

Jul 21, 2023, 8:20 AM EDT - 2 years ago

Turnstone Biologics set to go public as upsized $80 million IPO pricing at low end of expected range

Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering

Jul 21, 2023, 2:15 AM EDT - 2 years ago

Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering

IPO Update: Turnstone Biologics Readies $75 Million IPO Plan

Jul 17, 2023, 3:06 PM EDT - 2 years ago

IPO Update: Turnstone Biologics Readies $75 Million IPO Plan

Turnstone Biologics to offer 5.8 million shares in planned IPO priced at $12 to $14 each

Jul 17, 2023, 6:35 AM EDT - 2 years ago

Turnstone Biologics to offer 5.8 million shares in planned IPO priced at $12 to $14 each

Turnstone Biologics Begins $86 Million U.S. IPO Plan

Jun 14, 2023, 4:27 PM EDT - 2 years ago

Turnstone Biologics Begins $86 Million U.S. IPO Plan

DCZ
DCZ Jul. 16 at 5:27 PM
$TSBX is everyone tendering their shares? I held out on the first offer when this happened to BLUE and they made a better offer a few weeks later. I know this is a different situation but typically someone’s first offer is never their best offer.
1 · Reply
joe77w
joe77w Jun. 30 at 12:13 PM
$TSBX how much could be worth the CVR? 8/10 cents? Or less?
2 · Reply
Stmkr
Stmkr Jun. 28 at 5:41 AM
$TSBX $XOMA I dont get it. What does XOMA get from this acquisition??
1 · Reply
joe77w
joe77w Jun. 27 at 10:38 PM
$TSBX https://www.otcmarkets.com/filing/html?id=18580209&guid=nOi-kFPioonXB3h
0 · Reply
Chi_Booth
Chi_Booth Jun. 27 at 9:29 PM
$TSBX Looks like the net cash will be a separate distribution. As of last Q, they had $21M of cash and $7M of liabilities. They also appear to be selling certain assets to Moffit for $3M, which could be an additional upside. This deal could end up being a dollar or slightly under.
1 · Reply
ikkydiphoenix
ikkydiphoenix Jun. 27 at 8:50 PM
$TSBX Ms. Azmat will be eligible to receive, on the Azmat Separation Date, a cash severance payment in the amount of $354,327, COBRA benefits in the amount of $8,218.49, and outplacement services in the amount of up to $5,000. In addition, effective and contingent upon the closing of the Merger, Ms. Azmat will be entitled to receive an additional payment equal to $64,035. Ehi Good Job Guys, i could have reached a better deal with a 1000$ salary by the way :D
0 · Reply
ikkydiphoenix
ikkydiphoenix Jun. 27 at 8:49 PM
$TSBX Dr. Farah will be eligible to receive, on the Farah Separation Date, a cash severance payment in the amount of $686,757, COBRA benefits in the amount of $33,264.60, and outplacement services in the amount of up to $5,000. In addition, effective and contingent upon the closing of the Merger, Dr. Farah will be entitled to receive an additional payment equal to $148,874.68. LOL
0 · Reply
ikkydiphoenix
ikkydiphoenix Jun. 27 at 8:44 PM
$TSBX Each CVR holder will be entitled to the right to receive its portion of the amount equal to (i) up to an aggregate amount for all CVR holders of $1,110,000 to the extent received by the Company as a result of contingent payments relating to tax receivables and a lease security deposit, plus (ii) Net Cash Excess (as defined in the CVR Agreement), and minus (iii) Net Cash Shortfall (as defined in the CVR Agreement) (“CVR Proceeds”). In the event that any such CVR Proceeds are received after one year following the date of the closing of the Merger, holders of the CVRs will not receive any payment pursuant to the CVR Agreement.
1 · Reply
Chi_Booth
Chi_Booth Jun. 27 at 8:37 PM
$TSBX How do you accept an $8M BO offer when you have $20M in cash? If CVR is worth more than the cash value, why not spell it out for the shareholders? This is just messed up, and I am pissed at the level of incompetence. 😡
0 · Reply
Chi_Booth
Chi_Booth Jun. 27 at 8:28 PM
$TSBX This management team is seriously retarded!
0 · Reply
RETAlerts
RETAlerts Jun. 27 at 8:22 PM
A solid 10% gain for $TSBX at 0.423 since it first appeared on our radar. Keep tabs on the RSI and MACD indicators for clues on whether this momentum is sustainable. (15 minute delay)
0 · Reply
RETAlerts
RETAlerts Jun. 27 at 8:21 PM
$TSBX at 0.393 is showing some early promise, up since landing on our scanner. Could this be the start of a significant move? Stay tuned for updates. (15 minute delay)
0 · Reply
ikkydiphoenix
ikkydiphoenix Jun. 27 at 7:45 PM
$TSBX bought some at 0.35 .. maybe somebody will make a better offer, like it happened with $BLUE
0 · Reply
pav1n99
pav1n99 Jun. 27 at 4:07 PM
$TSBX
0 · Reply
Stmkr
Stmkr Jun. 27 at 3:58 PM
$XOMA $TSBX Is it typical for XOMA to acquire asset rights at such an early stage??
0 · Reply
joe77w
joe77w Jun. 27 at 3:45 PM
$TSBX https://www.fiercebiotech.com/biotech/turnstone-once-allied-abbvie-and-takeda-accepts-8m-xoma-buyout
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 27 at 3:32 PM
Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps $TSBX $XOMA https://stocktwits.com/news/equity/markets/turnstone-biologics-to-merge-with-biotech-royalty-aggregator-xoma/chmg6ZvRRIz
0 · Reply
Stmkr
Stmkr Jun. 27 at 3:15 PM
$TSBX Market currently valuing the CVR at just 0.01$...
0 · Reply
joe77w
joe77w Jun. 27 at 1:58 PM
$TSBX based on 23 mln shares each 2.3 mln usd asset monetization should be worth 10 cents, just my math
1 · Reply
ikkydiphoenix
ikkydiphoenix Jun. 27 at 11:54 AM
$TSBX considering the balance i could have sold this company for 0.35$ even without know its name, the CEO must be really dumb
0 · Reply
DonCorleone77
DonCorleone77 Jun. 27 at 11:52 AM
$XOMA $TSBX Xoma to acquire Turnstone Biologics for $0.34 in cash per share XOMA Royalty Corporation (XOMA) and Turnstone Biologics (TSBX) announced that they have entered into a definitive merger agreement, whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock plus one non-transferable contingent value right. Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best interests of all Turnstone stockholders and has approved the Merger Agreement and related transactions. Pursuant and subject to the terms of the Merger Agreement, XOMA Royalty will commence a tender offer by July 11, 2025, to acquire all outstanding shares of Turnstone common stock. Immediately following the closing of the tender offer, Turnstone will be acquired by XOMA Royalty, and all remaining shares not tendered in the offer, other than shares validly subject to appraisal, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer. Turnstone stockholders holding approximately 25.2% of Turnstone common stock have signed support agreements under which such stockholders have agreed to tender their shares in the Offer and support the merger transaction. The merger transaction is expected to close in August 2025.
0 · Reply
ikkydiphoenix
ikkydiphoenix Jun. 27 at 11:48 AM
$TSBX what is the CVR about?
0 · Reply